Treatment of Disseminated High Grade Lymphoma

French Innovative Leukemia Organisation100 enrolled

Overview

Interest of the use of pegylated liposomal doxorubicin (caélyx)

R CHOP is a good standard in the treatment of diffuse high grade lymphoma. Howeverin elderly patients it is often toxic, specially with haematologic and cardiac toxicities.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Lymphoma

Interventions

DoxorubicinDRUG

Doxorubicin pegylatedDRUG

Eligibility

Sex: ALLMin age: 60 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * high grade lymphoma * disseminated * \> 60 years old and \< 75 * informed consent signed * cardiac state compatible with antracyclin * ECOG \</= 2 Exclusion Criteria: * patients \> 75 years old * Cardiac insufficiency

Locations (1)

Clinique Victor Hugo

Le Mans, France

Outcomes

Primary Outcomes

hematologic toxicity

Time frame: 6 months

Secondary Outcomes

response rate

Time frame: 6 months

EFS and OS

Time frame: 6 months

Cardiac toxicity

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.